Soligenix

#药闻简讯# 2025 年 10 月 7 日,专注于开发和商业化治疗罕见病产品的后期生物制药公司$Soligenix(SNGX)$ 今日宣布，其针对 HyBryte™（合成金丝桃素）治疗皮肤 T 细胞淋巴瘤（CTCL）的确认性 3 期临床试验的首个数据监测委员会（DMC）会议已结束。该会议认为，正在进行中的 3 期临床试验没有安全...

$Soligenix(SNGX)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001104659-25-072708  Act: 34  Size: 307 KB 网页链接

$Soligenix(SNGX)$ 8-K Current report, items 3.01 and 9.01 Accession Number: 0001558370-25-011619  Act: 34  Size: 165 KB 网页链接

$Soligenix(SNGX)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001558370-25-011618  Act: 33  Size: 1 MB 网页链接

$Soligenix(SNGX)$ S-1 General form for registration of securities under the Securities Act of 1933 Accession Number: 0001104659-25-091717  Act: 33  Size: 21 MB 网页链接

$Soligenix(SNGX)$ 8-K Current report, items 1.01, 8.01, and 9.01 Accession Number: 0001104659-25-094507  Act: 34  Size: 1 MB 网页链接

$Soligenix(SNGX)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001558370-25-011625  Act: 34  Size: 224 KB 网页链接

$Soligenix(SNGX)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001558370-25-011617  Act: 33  Size: 1 MB 网页链接

$Soligenix(SNGX)$ 424B4 Prospectus [Rule 424(b)(4)] Accession Number: 0001104659-25-093934  Act: 33  Size: 3 MB 网页链接

$Soligenix(SNGX)$ SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors Accession Number: 0001213900-25-094732  Act: 34  Size: 21 KB 网页链接

$Soligenix(SNGX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001068029-25-000003  Size: 5 KB 网页链接

$Soligenix(SNGX)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001558370-25-011620  Act: 33  Size: 1 MB 网页链接

$Soligenix(SNGX)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001558370-25-011554  Act: 34  Size: 7 MB 网页链接

$Soligenix(SNGX)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-25-003103  Act: 33  Size: 2 KB 网页链接